Arginase Inhibition in Type 1 and Type 2 Diabetes Mellitus

NCT05806502 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-06-21

No results posted yet for this study

Summary

To evaluate the efficacy of arginase inhibition on endothelial function in patients with type 1 diabetes and type 2 diabetes.

Conditions

Interventions

DIAGNOSTIC_TEST

Nω-hydroxy-nor-arginine

Arginase inhibitor

Sponsors & Collaborators

Principal Investigators

  • John Pernow, MD · Karolinska Institutet

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2023-04-30
Completion
2023-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05806502 on ClinicalTrials.gov